CYRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cryoport, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$16.98+0.14 (+0.83%)
Close on Oct 19, 2026
- Market cap
- $856.52M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2010 to 2025
Gross margin
47.1%+1.0 pts over 5 years
Operating margin
-20.9%+17.2 pts over 5 years
Net margin
44.4%+86.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +12.4% | -9.4% | +17.5% | +46.3% | |
| Gross profit | +19.2% | -7.2% | +18.0% | +53.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 516.5% | -12.8% | 17.3% | |
| Return on assets | -325.6% | -9.5% | 10.7% | |
| Current ratio | 0.72 | 4.20 | 2.17 | |
| Debt to equity | – | 0.01 | 0.00 | |
| Net debt to EBITDA | – | 1.59× | 27.43× | |
| Interest coverage | -3.9× | -11.7× | -15.6× | |
| Inventory turnover | 55.7× | 7.7× | 4.2× | |
| Capex to revenue | 1.8% | 11.3% | 9.3% | |
| Diluted shares | 5M | 39M | 50M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cryoport generated $35.64M from operations and spent $166.44M on capital expenditure, dividends and share buybacks. 71% of that went back into the business.
Generated
$35.64M
Used
$166.44M
Capital expenditure$118.47M71%Dividends$00%Share buybacks$47.97M29%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin44.4%
×Asset turnover0.24×
×Equity multiplier1.62×
=Return on equity, FY202517.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 44.4% | 0.24× | 1.62× | 17.3% |
| FY2024 | -73.2% | 0.19× | 1.86× | -25.8% |
| FY2023 | -59.0% | 0.17× | 1.91× | -19.1% |
| FY2022 | -15.7% | 0.22× | 1.80× | -6.2% |
| FY2021 | -123.8% | 0.27× | 1.63× | -53.8% |
| FY2020 | -41.5% | 0.23× | 1.35× | -12.8% |
| FY2019 | -54.0% | 0.35× | 1.17× | -22.2% |
| FY2016 | -167.0% | 1.40× | 3.15× | -733.0% |
| FY2015 | -178.6% | 1.82× | -1.59× | 516.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$78.30M
- Cash generatingOperating cash flow above zero-$8.58M
- Return on assets improvedROA up on the prior year-12.0% → 11.1%
- Earnings backed by cashOperating cash flow above net income-$8.58M vs $78.30M
- Less leverageLong-term debt to assets fell0.2% → 0.1%
- Better liquidityCurrent ratio rose5.29 → 2.17
- No dilutionShare count did not rise49M → 50M
- Gross margin improvedGross margin up on the prior year44.43% → 47.14%
- More efficientAsset turnover rose0.16 → 0.25